Metoprolol Tartrate Tablets, USP, 50 mg, 1000 Tablets, Rx Only, Manufactured by: Renata PLC (Gene...

FDA Drug Recall #D-0581-2025 — Class II — August 6, 2025

Recall Summary

Recall Number D-0581-2025
Classification Class II — Moderate risk
Date Initiated August 6, 2025
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Westminster Pharmaceuticals LLC
Location Nashville, TN
Product Type Drugs
Quantity 16,672 1000-count bottles

Product Description

Metoprolol Tartrate Tablets, USP, 50 mg, 1000 Tablets, Rx Only, Manufactured by: Renata PLC (General Plant -2), Noyapara, Bhawal Mirzapur, Rajendrapur, Gazipur, 1700 Bangladesh, Distributed by: Westminster Pharmaceuticals, LLC, Nashville, TN 37217, NDC 69367-354-10

Reason for Recall

CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.

Distribution Pattern

Nationwide in the USA.

Lot / Code Information

Batch # R55230021, R55230031, R55230041, Exp Date: 9/30/25; Batch # R55230051, R55230061, R55230071, R55230081, R55230091, R55230101, R55230111, R55230121, R55230131, R55230141, Exp Date: 10/31/2025; Batch # R55230151, Exp Date: 11/30/25; Batch # R55240011, Exp Date: 12/31/25; Batch # R55240021, R55240031, R55240041, R55240051, R55240061, Exp Date: 6/30/26; Batch # R55240071, R55240081, R55240091, R55240101, R55240111, R55240121, Exp Date: 7/31/26

Other Recalls from Westminster Pharmaceuticals LLC

Recall # Classification Product Date
D-0582-2025 Class II Metoprolol Tartrate Tablets, USP, 100 mg, 1000 ... Aug 6, 2025
D-0300-2019 Class II Westminster Irbesartan Tablets, USP 75 mg Rx On... Oct 29, 2018
D-0302-2019 Class II Westminster Irbesartan Tablets, USP 300 mg Rx O... Oct 29, 2018
D-0301-2019 Class II Westminster Irbesartan Tablets, USP 150 mg Rx O... Oct 29, 2018
D-1178-2018 Class I Levothyroxine and Liothyronine (Thyroid Tablets... Aug 3, 2018

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.